Positive clinical results from tirzepatide (originally named LY3298176) (15–17), a long-acting “sequence-mixed” GIP and GLP-1 receptor agonist, led to FDA approval for T2DM and obesity treatment. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.